Announcements Trials
Browse Landscape

Phase

Phase 3 19Phase 2 11Phase NA 4Phase 2/3 3Phase 4 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Vomiting 2Nausea 2Postoperative Nausea and Vomiting 1Neoplasms 1Muscular Atrophy 1Child Nutrition Disorders 1

Interventions

Cisplatin 54Cyclophosphamide 42Fluorouracil 41Oxaliplatin 36Capecitabine 35Docetaxel 34Gemcitabine 32Drug Therapy 32Radiotherapy 31Paclitaxel 25Dexamethasone 23Carboplatin 23Leucovorin 21Etoposide 17Doxorubicin 17Cytarabine 17apatinib 16Methotrexate 16Magnetic Resonance Spectroscopy 14Radiation 13Epirubicin 13Busulfan 13Bevacizumab 13Surgical Procedures, Operative 12Neoadjuvant Therapy 12Letrozole 12Decitabine 12Saline Solution 11Irinotecan 11venetoclax 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × Olanzapine × Clear all
NCT06175273 2025-09-18

POINT

University of Kentucky

Phase 2/3 Completed
19 enrolled

Muscular Atrophy, Neoplasms, Child Nutrition Disorders

NCT03631004 2022-01-13

Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients

Instituto do Cancer do Estado de São Paulo

Phase 2/3 Completed
100 enrolled

Nausea, Vomiting, Postoperative Nausea and Vomiting

NCT03137121 2021-08-17

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients

University of Alabama at Birmingham

Phase 2/3 Completed
30 enrolled 9 charts

Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡